- Conditions
- Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
- Interventions
- Talazoparib with enzalutamide, Talazoparib
- Drug
- Lead sponsor
- Prostate Cancer Clinical Trials Consortium
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 8
- States / cities
- Duarte, California • La Jolla, California • Boston, Massachusetts + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Prostate Cancer
- Interventions
- Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
- Drug · Radiation
- Lead sponsor
- University of Sydney
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 19
- States / cities
- Boston, Massachusetts • Brighton, Massachusetts • Burlington, Massachusetts + 15 more
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Enzalutamide, Prednisone
- Drug
- Lead sponsor
- Prostate Cancer Clinical Trials Consortium
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 2 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Sacramento, California • Aurora, Colorado • Tampa, Florida + 19 more
- Conditions
- Prostate Cancer
- Interventions
- Not listed
- Lead sponsor
- Prostate Cancer Clinical Trials Consortium
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2037
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • New York, New York • Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- Standard of Care
- Other
- Lead sponsor
- Prostate Cancer Clinical Trials Consortium
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Los Angeles, California + 35 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v7
- Interventions
- Enzalutamide, Ribociclib, Laboratory Biomarker Analysis, Pharmacological Study, Biospecimen Collection, Biopsy, Echocardiography, Multigated Acquisition Scan, Bone Scan, Computed Tomography, Magnetic Resonance Imaging
- Drug · Other · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 4
- States / cities
- Ann Arbor, Michigan • Buffalo, New York • New York, New York + 1 more
- Conditions
- Prostate Cancer
- Interventions
- ATN-224
- Drug
- Lead sponsor
- Attenuon
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 6
- States / cities
- San Francisco, California • Baltimore, Maryland • New York, New York + 3 more
- Conditions
- Prostate Cancer
- Interventions
- Seviteronel: given orally once daily in 28-day cycles
- Drug
- Lead sponsor
- Innocrin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 17 more
- Conditions
- Prostate Carcinoma Metastatic to the Bone, Stage IV Prostate Adenocarcinoma, Hormone-refractory Prostate Cancer
- Interventions
- Niraparib, Radium Ra 223 Dichloride
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Chicago, Illinois • New Orleans, Louisiana + 2 more
- Conditions
- Prostate Cancer
- Interventions
- Muscadine Plus Grape Skin Extract, Low-dose MPX, High-dose MPX, Placebo oral capsule
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 8
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 3 more